Protagonist Therapeutics
PTGX
140.92
+2.23
+1.61%
Protagonist Therapeutics
US · PTGX
#1570 by market cap
Listed 2016
140.92
+2.23
+1.61%
Live - 5344 symbols - heartbeat 117s ago
· 2026-10-08 08:20
Pre-market
140.10
-0.58%
After-hours
140.92
0.00%
- Market cap
- 9.12B
- P/E (TTM)i
- 136.82
- P/Bi
- 10.84
- EPSi
- -2.05
- Div yieldi
- 0.00%
- 52W posi
- 77%
Reader sentiment
Are you bullish or bearish on PTGX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 101.56, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -89.41% YoY
Margins
- Operating margin
- -343.63%
- Net margin
- -282.83%
Key ratios & quality
- Altman Z-Scorei
- 101.56
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 30.93M | 231.00K | 28.63M | 27.36M | 26.58M | 60.00M | 434.43M | 46.02M |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 13.70M | 15.75M | 18.64M | 27.20M | 31.74M | 33.49M | 43.46M | 44.85M |
| Research & development | 59.50M | 65.00M | 74.51M | 126.01M | 126.22M | 120.16M | 138.13M | 159.29M |
| Operating profit | -42.27M | -80.52M | -64.52M | -125.85M | -131.37M | -93.65M | 252.84M | -158.13M |
| Pretax profit | -39.72M | -77.88M | -64.85M | -125.55M | -127.39M | -78.96M | 279.41M | -129.31M |
| Tax | -799.00K | -691.00K | 1.31M | -- | 0 | 0 | 4.22M | 838.00K |
| Net profit | -38.92M | -77.19M | -66.15M | -125.55M | -127.39M | -78.96M | 275.19M | -130.15M |
| Basic EPS | -2 | -3 | -2 | -3 | -3 | -1 | 4 | -2 |
| Diluted EPS | -1.74 | -2.98 | -1.92 | -2.71 | -2.60 | -1.39 | 4.23 | -2.05 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 28.32M | 5.55M | 4.71M | 7.44M | 56.37M | 213.48M |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 11.74M | 10.55M | 11.13M | 11.43M | 13.28M | 12.65M |
| Research & development | 35.89M | 37.04M | 40.00M | 46.36M | 46.74M | 42.06M |
| Operating profit | -19.31M | -42.04M | -46.42M | -50.36M | -3.65M | 158.77M |
| Pretax profit | -11.66M | -34.60M | -39.34M | -43.72M | 2.28M | 165.11M |
| Tax | 0 | 172.00K | 0 | 666.00K | -1.50M | 2.27M |
| Net profit | -11.66M | -34.77M | -39.34M | -44.38M | 3.78M | 162.85M |
| Basic EPS | 0 | -1 | -1 | -1 | 0 | 2 |
| Diluted EPS | -0.19 | -0.55 | -0.62 | -0.69 | 0.05 | 2.29 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 137.50M | 145.31M | 315.61M | 340.74M | 243.08M | 355.58M | 591.64M | 577.57M |
| Cash & ST investments | 128.85M | 133.02M | 305.81M | 326.90M | 237.36M | 341.62M | 418.91M | 567.36M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 139.47M | 154.92M | 324.47M | 347.70M | 247.93M | 357.95M | 744.73M | 668.19M |
| Total current liabilities | 26.16M | 35.41M | 40.24M | 44.02M | 31.18M | 21.27M | 47.40M | 45.44M |
| Short-term debt | -- | 1.26M | 1.46M | 2.20M | 2.52M | 1.14M | 510.00K | 2.28M |
| Long-term debt | -- | 9.79M | -- | -- | -- | -- | -- | -- |
| Total liabilities | 26,957,000.00 | 74,953,000.00 | 44,862,000.00 | 47,674,000.00 | 32,320,000.00 | 21,274,000.00 | 69,430,000.00 | 53,481,000.00 |
| Total equity | 112.52M | 79.96M | 279.61M | 300.02M | 215.61M | 336.68M | 675.30M | 614.71M |
| Retained earnings | -140.47M | -217.66M | -283.81M | -409.36M | -536.76M | -615.71M | -340.52M | -470.67M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 605.86M | 602.53M | 586.42M | 577.57M | 613.46M | 807.15M |
| Cash & ST investments | 574.36M | 570.47M | 576.12M | 567.36M | 547.79M | 782.58M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 742.13M | 718.01M | 701.69M | 668.19M | 697.46M | 885.54M |
| Total current liabilities | 35.11M | 35.51M | 44.94M | 45.44M | 34.55M | 37.18M |
| Short-term debt | 1.57M | 2.17M | 2.23M | 2.28M | 2.34M | 2.40M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 53,080,000.00 | 49,988,000.00 | 56,251,000.00 | 53,481,000.00 | 41,986,000.00 | 44,001,000.00 |
| Total equity | 689.05M | 668.02M | 645.44M | 614.71M | 655.47M | 841.54M |
| Retained earnings | -352.18M | -386.95M | -426.29M | -470.67M | -466.89M | -304.04M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -49.95M | -41.53M | -72.48M | -107.87M | -108.14M | -70.24M | 184.15M | 57.67M |
| Depreciation & amortization | 527.00K | 732.00K | 948.00K | 813.00K | 1.03M | 977.00K | 826.00K | 1.28M |
| Free cash flow | -50.43M | -42.49M | -72.96M | -108.97M | -108.93M | -70.85M | 182.80M | 56.08M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 23.18M | 34.49M | 255.37M | 123.83M | 14.55M | 132.10M | 0 | 0 |
| Ending cash balance | 82.69M | 33.47M | 117.82M | 123.89M | 125.97M | 186.95M | 97.47M | 128.68M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 125.36M | -28.78M | -1.94M | -36.98M | -48.94M | 219.05M |
| Depreciation & amortization | 239.00K | 304.00K | 361.00K | 376.00K | 407.00K | 397.00K |
| Free cash flow | 124.82M | -29.59M | -2.03M | -37.12M | -49.16M | 218.88M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 139.88M | 168.83M | 114.00M | 128.68M | 194.00M | 420.37M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -33.39 | -80.20 | -36.79 | -43.32 | -49.41 | -28.59 | 54.39 | -20.18 |
| ROA %i | -25.68 | -52.44 | -27.60 | -37.36 | -42.78 | -26.06 | 49.91 | -18.42 |
| ROIC %i | -35.53 | -70.47 | -34.70 | -42.61 | -50.06 | -33.69 | 48.69 | -23.32 |
| 5-year avg ROE %i | -- | -- | -62.27 | -45.84 | -48.62 | -47.66 | -20.75 | -17.42 |
| EBIT margin %i | -136.68 | -33,640.26 | -224.42 | -458.94 | -479.26 | -156.09 | 58.20 | -343.63 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | 42.08 | 121.87 |
| Current ratioi | 5.26 | 4.10 | 7.84 | 7.74 | 7.80 | 16.71 | 12.48 | 12.71 |
| Quick ratioi | 5.16 | 3.95 | 7.69 | 7.55 | 7.61 | 16.54 | 12.39 | 12.58 |
| Debt / assetsi | 0.00 | 10.98 | 1.84 | 1.68 | 1.47 | 0.32 | 1.46 | 1.54 |
| LT debt / equityi | -- | 19.70 | 1.61 | 1.22 | 0.53 | -- | 1.53 | 1.31 |
| Interest coveragei | -- | -459.82 | -107.44 | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | 12.58 | -4.00 | 386.39 | 27.97 | 151.35 | 20.07 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 8.99 | 8.61 | 7.80 | -20.18 | -17.06 | 10.98 |
| ROA %i | 8.19 | 7.81 | 7.03 | -18.42 | -15.94 | 10.34 |
| ROIC %i | 4.27 | 3.81 | 3.06 | -23.32 | -20.74 | 7.48 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 13.10 | 11.46 | 9.09 | -343.63 | -192.36 | 20.69 |
| FCF / sales %i | 161.35 | 17.74 | 30.45 | 121.87 | -- | 46.31 |
| Current ratioi | 17.26 | 16.97 | 13.05 | 12.71 | 17.76 | 21.71 |
| Quick ratioi | 17.13 | 16.85 | 12.94 | 12.58 | 17.51 | 21.58 |
| Debt / assetsi | 1.53 | 1.57 | 1.53 | 1.54 | 1.40 | 1.04 |
| LT debt / equityi | 1.42 | 1.36 | 1.32 | 1.31 | 1.13 | 0.81 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Discovery and development of innovative medicines in areas of unmet medical need100.00%
Quote time 2026-10-08 08:20:39 · For reference only, not investment advice and not tailored to your situation.